Overview
- Warhound publicly launched in late October 2026 with a reported $200 million seed round to pursue dogs for military, police and emergency use.
- The company was conceived by Palmer Luckey and Ben Lamm and is led by CEO David Spirk, with Colossal Biosciences licensing gene‑editing work and Anduril supplying external protective and sensor gear.
- Warhound’s stated plan combines three steps: collect and biobank DNA from top performers, clone proven dogs and screen or edit genes to remove disease variants and potentially enhance traits.
- Animal‑welfare groups and bioethicists have sharply criticized the project, warning about cloning failures, off‑target genetic effects, the psychological harm to engineered animals and unclear plans for dogs that do not meet standards.
- Warhound has not announced government contracts or pricing, regulatory clearance remains unresolved, and critics note robotic alternatives and procurement, training and welfare questions that could delay or limit adoption.